CATUG was founded in 2021 and has rapidly emerged as a leading provider of mRNA therapeutic research tools, supporting the development of mRNA-based therapies as well as gene and cell therapy products, from the initial concept to launch the product into the market. CATUG delivers comprehensive, end-to-end solutions customized to meet your unique requirements, complemented by their product range.
With expertise in plasmid DNA, mRNA, and LNP technologies, CATUG delivers seamless, end-to-end solutions tailored to meet your specific needs. Their proprietary CatPure™ range is designed to accelerate pre-clinical studies by providing high-quality, research-grade mRNA that enhances both purity and expression levels.
Optimized Design for Maximum Expression: Each mRNA is fully sequence-optimized (CDS + UTR) and selected from over 20 variants to achieve the highest expression levels.
Rigorous Production Process: Manufacturing follows tightly controlled IVT, oligo-dT purification, and TFF protocols, ensuring minimal batch-to-batch variability. Every batch undergoes comprehensive quality checks with IND-grade release specifications, including in vitro and cellular potency validation.
Proven Performance: Extensively tested and validated by academic and industry leaders, CatPure™ mRNAs have demonstrated exceptional effectiveness across diverse applications.
